| Literature DB >> 25889861 |
Akiko Abe1, Maki Matoda2, Sanshiro Okamoto3, Eiji Kondo4, Kazuyoshi Kato5, Kohei Omatsu6, Kenji Umayahara7, Kuniko Utsugi8, Nobuhiro Takeshima9.
Abstract
BACKGROUND: We describe our experiences with vaginal vault resection for vaginal recurrence of cervical cancer after hysterectomy and radiotherapy. After operative treatment, the rate of vaginal vault recurrence of uterine cervical cancer is reported to be about 5%. There is no consensus regarding the treatment for these cases.Entities:
Mesh:
Year: 2015 PMID: 25889861 PMCID: PMC4387660 DOI: 10.1186/s12957-015-0495-8
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Clinical features of the patients at the initial operation
|
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|
| Age | 69 | 35 | 43 | 41 | 33 | 30 | 44 | 49 |
| Initial stage | 0 | 0 | 0 | Ia | Ia | Ia | IIa | IIb |
| Histology | AS | CIS | AIS | SCC | AC | SCC | SCC | AS |
| Initial operation | TAH | TAH | MRH + BSO + PLA | TAH | RH + BSO + PLA | VTH | MRH + BSO | RH + BSO + PLA |
| Vaginal margin | Negative | Positive | Negative | NA | Negative | Positive | Positive | NA |
| Adaptation of radiation treatment | Adjuvant | Recurrence | Recurrence | Adjuvant | Recurrence | Recurrence | Adjuvant | Recurrence |
| Interval between initial operation and vaginectomy | 12 M | 13 M | 44 M | 12 M | 9 M | 38 M | 12 M | 10 M |
AS, adenosquamous cell carcinoma; CIS, carcinoma in situ; AIS, adenocarcinoma in situ; SCC, squamous cell carcinoma; AC, adenocarcinoma; TAH, total abdominal hysterectomy; MRH, modified radical hysterectomy; BSO, bilateral salpingo-oophorectomy; PLA, pelvic lymphadenectomy; RH, radical hysterectomy; VTH, vaginal total hysterectomy; NA, not available.
Figure 1The vaginal apex identified using Hegar sounds and pulled via the apex (A) and pelvic appearance after vaginectomy (B).
Figure 2The vaginal appearance after the operation (A) and the dissected vaginal specimen (B).
Clinical feature of the patients at vaginectomy
|
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|
| Age | 70 | 36 | 48 | 44 | 35 | 36 | 46 | 54 |
| Operative time (min), for vaginectomy | 180 | 590 | 219 | 172 | 270 | 316 | 191 | 442 |
| Blood loss, mL | 250 | 1,890 | 49 | 150 | 365 | 490 | 360 | 760 |
| Intraoperative complications | Rectal injury G1 | None | Bladder injury G1 | None | None | None | None | None |
| Postoperative complications | Cystitis | Vesicovaginal fistula (POD33) | Vesicovaginal fistula (POD40), ileus, nephritis | None | None | Nephritis | Vesicovaginal fistula (POD19), nephritis | Stump bleeding |
| Self-catheterization | No | No | No | No | + | No | No | + |
| Margin of resection | Positive | Positive | Unclear | Positive | Negative | Positive | Negative | Negative |
| Site of recurrence after colpectomy | PLN | Pelvic wall | Vulva | No | No | PAN | No | Vulva PLN |
| Treatment for recurrence after colpectomy | Radiation | Exenteration | Vulvectomy | Chemotherapy | Vulvectomy + lymphadenectomy | |||
| Time to recurrence from colpectomy | 10 M | 2 M | 6 M | 22 M | 19 M | |||
| Final status | AWD | DOD | AWD | NED | NED | AWD | NED | AWD |
POD, postoperative day; PLN, pelvic lymph node; PAN, para-aortic lymph node; AWD, alive with disease; DOD, dead of disease; NED, no evidence of disease.
Figure 3Urethrocystography showing a vesicovaginal fistula (arrow) (A, B).